Siyuan Shen

Julia Bazinska, Andrei Ivanov, Tal Ben-Nun et al.

Graph Neural Networks (GNNs) are a powerful tool for handling structured graph data and addressing tasks such as node classification, graph classification, and clustering. However, the sparse nature of GNN computation poses new challenges for performance optimization compared to traditional deep neural networks. We address these challenges by providing a unified view of GNN computation, I/O, and memory. By analyzing the computational graphs of the Graph Convolutional Network (GCN) and Graph Attention (GAT) layers -- two widely used GNN layers -- we propose alternative computation strategies. We present adaptive operator reordering with caching, which achieves a speedup of up to 2.43x for GCN compared to the current state-of-the-art. Furthermore, an exploration of different caching schemes for GAT yields a speedup of up to 1.94x. The proposed optimizations save memory, are easily implemented across various hardware platforms, and have the potential to alleviate performance bottlenecks in training large-scale GNN models.

J. Wang, X. Liu, S. Shen et al.

Drug combination therapy has become a increasingly promising method in the treatment of cancer. However, the number of possible drug combinations is so huge that it is hard to screen synergistic drug combinations through wet-lab experiments. Therefore, computational screening has become an important way to prioritize drug combinations. Graph neural network have recently shown remarkable performance in the prediction of compound-protein interactions, but it has not been applied to the screening of drug combinations. In this paper, we proposed a deep learning model based on graph neural networks and attention mechanism to identify drug combinations that can effectively inhibit the viability of specific cancer cells. The feature embeddings of drug molecule structure and gene expression profiles were taken as input to multi-layer feedforward neural network to identify the synergistic drug combinations. We compared DeepDDS with classical machine learning methods and other deep learning-based methods on benchmark data set, and the leave-one-out experimental results showed that DeepDDS achieved better performance than competitive methods. Also, on an independent test set released by well-known pharmaceutical enterprise AstraZeneca, DeepDDS was superior to competitive methods by more than 16\% predictive precision. Furthermore, we explored the interpretability of the graph attention network, and found the correlation matrix of atomic features revealed important chemical substructures of drugs. We believed that DeepDDS is an effective tool that prioritized synergistic drug combinations for further wet-lab experiment validation.